Abstract
Background: New continuous flow left ventricular assist devices (LVAD) are smaller and quieter than existing pulsatile volume displacement devices, with the ability to provide improved quality of life for advanced heart failure patients. We assessed the impact of such a device on functional capacity and heart failure-related quality of life. Methods: Data from 231 patients enrolled in a clinical trial of the HeartMate II LVAD (HMII) implanted for bridge to transplantation at 35 centers were analyzed.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
